NLRX1 (NLR Family Member X1) is a uniquely localized member of the NOD-like receptor family that is anchored to the mitochondrial outer membrane, distinguishing it from most NLR that reside in the cytosol[1]. This mitochondrial positioning allows NLRX1 to serve as a critical interface between mitochondrial function and innate immune signaling, regulating antiviral responses, oxidative stress, and cell death pathways that are all relevant to neurodegenerative disease pathogenesis[2]. NLRX1 is expressed in multiple tissues, including the brain, where it is found in neurons, astrocytes, and microglia.
| Property | Value |
|---|---|
| Gene Symbol | NLRX1 |
| Official Name | NLR Family Member X1 |
| Aliases | NOD5, FLYWCH1 |
| Chromosomal Location | 6q16.1 |
| NCBI Gene ID | 79671 |
| UniProt ID | Q9NWV8 |
| Ensembl ID | ENSG00000170873 |
| Protein Class | NOD-like receptor |
The NLRX1 protein (~977 amino acids) contains several functional domains:
The mitochondrial localization is unique among NLR family members and positions NLRX1 to sense mitochondrial dysfunction and communicate with cytosolic signaling pathways.
NLRX1 was originally characterized as a positive regulator of RIG-I-like receptor (RLR) signaling. Upon detection of viral RNA in the cytosol, NLRX1 interacts with MAVS (Mitochondrial Antiviral Signaling Protein) to enhance downstream NF-κB and IRF activation, leading to production of type I interferons and pro-inflammatory cytokines[1:2].
NLRX1 plays a critical role in modulating mitochondrial reactive oxygen species (ROS) production:
NLRX1 negatively regulates multiple inflammasome complexes:
NLRX1 influences both apoptotic and necroptotic cell death pathways:
In Alzheimer's disease, NLRX1 exhibits both protective and disease-modifying roles:
NLRX1 is highly relevant to Parkinson's disease pathogenesis:
In ALS, NLRX1 provides important regulatory functions:
In the brain, NLRX1 is expressed in:
Expression levels vary by brain region, with higher expression in areas vulnerable to neurodegenerative processes.
NLRX1 represents a promising therapeutic target:
Key questions in NLRX1 research:
Moore CB, et al. NLRX1 is a regulator of mitochondrial antiviral immunity. Nature. 2008. ↩︎ ↩︎ ↩︎
Kigerl KA, et al. NLRX1 regulates inflammatory and homeostatic glial cell responses in the CNS. J Neuroinflammation. 2022. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Arnoult D, et al. A mitochondrial pathway of innate immune signaling. Nat Rev Immunol. 2021. ↩︎ ↩︎
Yang L, et al. NLRX1 attenuates oxidative stress and mitochondrial dysfunction in Parkinson's disease models. Free Radic Biol Med. 2020. ↩︎ ↩︎ ↩︎
Khalsa JK, et al. AIM2 inflammasome regulation by NLRX1. Nat Immunol. 2019. ↩︎
Kuriakose T, Kanneganti TD. ZBP1 and necroptosis in immunity and inflammation. Nat Rev Immunol. 2023. ↩︎
Xu W, et al. MTCH2 is a novel NLRX1 interactor regulating cell death. Cell Death Differ. 2024. ↩︎
Liu Y, et al. NLRX1 upregulation in Alzheimer's disease brain correlates with disease pathology. Acta Neuropathol Commun. 2021. ↩︎ ↩︎
Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron. 2015. ↩︎ ↩︎ ↩︎
Sarkar S, et al. Mitochondrial dysfunction in Parkinson's disease: Molecular insights into therapeutic potential. Neurobiol Dis. 2020. ↩︎
Yamaguchi T, et al. TDP-43 pathology in ALS and FTD. Acta Neuropathol. 2023. ↩︎
Cookson MR. Mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci. 2022. ↩︎